Life Sciences Consortium (LSC)

At a Glance

- Status: Active Consortium
- Year Launched: 2005
- Initiating Organization: CEO Roundtable on Cancer
- Initiator Type: Third-party organization
- Location: North America

Abstract

The Life Sciences Consortium (LSC) is a task force of the CEO Roundtable on Cancer. LSC was formed in 2005 to bring together selected CEO Roundtable on Cancer member companies to build collaboration that enables a transformation in research and development (R&D) activities that will deliver more effective therapies to patients faster. LSC hopes that its website visitors will use its resources and share their own relevant insights in a collaborative effort to better serve cancer patients worldwide.

Mission

LSC’s overarching goal is to enable member companies to work together to remove roadblocks and to find new ways to accelerate discovery and development of new therapies for all cancer patients.

Specific tactics include the following:
Consortium History

An LSC Task Force was commissioned during the fourth annual meeting of the CEO Roundtable on Cancer in June 2003. The Task Force was asked to explore the creation of a forum to enhance and speed cancer drug discovery and early drug development, thereby bringing improved therapies to cancer patients faster. LSC was charged with exploring the formation of a consortium that would unite the research-intensive pharmaceutical and biotech industry with each other, as well as with the National Cancer Institute, Centers for Disease Control and Prevention, U.S. Food and Drug Administration, and academic centers of excellence.

Impact/Accomplishment

Project Data Sphere, LLC, an independent, not-for-profit initiative of LSC, operates the Project Data Sphere® platform (www.ProjectDataSphere.org), which provides one place where the research community can broadly share, integrate, and analyze historical, patient-level, cancer Phase III comparator-arm data with the goal of advancing future research to improve the lives of cancer patients and their families around the world.

The START clauses represent a toolkit that provides standardized legal language for key agreement elements common to most clinical trial agreements. By starting the negotiation process with commonly agreed upon language, the START clauses can simplify and accelerate the contracting process. Although developed with cancer clinical trials in mind, the START clauses are applicable to all types of clinical research.

Links/Social Media Feed

Homepage http://ceo-lsc.org/

Points of Contact

Gregory A. Curt
Co-Chair, Life Sciences Consortium
email: Gregory.Curt@astrazeneca.com
Mace Rothenberg  
Co-Chair, Life Sciences Consortium  
email: Mace.Rothenberg@pfizer.com

Sponsors & Partners

Amgen  
Astellas Pharma, Inc.  
AstraZeneca  
Bayer HealthCare Pharmaceuticals Inc.  
Boehringer Ingelheim Pharmaceuticals  
Celgene  
Centocor R&D USA  
CEO Roundtable on Cancer  
Covance  
Duke University School of Medicine  
Eli Lilly and Company  
H. Lee Moffitt Cancer Center and Research Institute  
Hogan Lovells US LLP  
Institute of Medicine  
Johnson & Johnson  
MD Anderson Cancer Center  
MedImmune  
Mehta Partners  
Novartis  
Pfizer, Inc.  
PPD  
Quintiles Transnational  
Sanofi  
SAS  
The LIVESTRONG Foundation  
The National Cancer Institute